Sunshine Biopharma has signed an agreement with The Research Foundation of the State University of New York, acting on behalf of Binghamton University, to develop Sunshine lead compound Adva-27a for the treatment of breast and prostate cancer.
Under the agreement, the parties will conduct necessary research and development to accelerate Adva-27a through various stages of preclinical development and Phase I clinical trials.
The agreement will be in force for three years and shall be renewed automatically for additional year-long periods until the project is completed
Sunshine president and CEO Dr Steve Slilaty said the company was very excited to sign the agreement with Binghamton University.
“We anticipate completion by the first half of 2012 and, if things go as we expect, we anticipate Adva-27a to be available for compassionate-use by the end of the trial,” Slilaty added.
Adva-27a is a small molecule inhibitor of Topoisomerase II, an enzyme found in abundance in multi-drug resistant breast cancer as well as in other types of aggressive cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData